Welcome to our dedicated page for Sage Therapeutics news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutics stock.
Sage Therapeutics, Inc. (SAGE) is a pioneering, neuroscience-focused biopharmaceutical company dedicated to developing medicines for life-threatening and rare central nervous system (CNS) disorders. Founded in 2010, Sage Therapeutics aims to improve the lives of patients suffering from various CNS diseases through breakthrough scientific research, robust clinical trials, and strong partnerships.
The company is primarily engaged in three key focus areas: depression, neurology, and neuropsychiatry. Sage's lead compound, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE), marking the first of many potential seizure medicines in its extensive pipeline. Another notable treatment, Zurzuvae, targets postpartum depression (PPD) in adults, while Zulresso is a CIV injection designed for individuals aged 15 and older dealing with PPD.
In addition to these approved treatments, the company’s pipeline features several promising compounds, including SAGE-324 and Dalzanemdor (SAGE-718), which are currently under various stages of development. Sage Therapeutics leverages two critical CNS receptor systems, GABA and NMDA, to develop its innovative treatments.
Sage’s commitment to compelling science and robust clinical foundations is fortified by its world-class team of founders, advisors, investors, scientists, and managers. The company prides itself on its collaborative efforts, fostering strategic partnerships to enhance its research and development capabilities. These efforts underscore Sage Therapeutics' mission to discover, develop, and deliver significant new medicines to address unmet medical needs in the CNS space.
Sage Therapeutics and Biogen announced disappointing topline results from their Phase 2 KINETIC 2 study of SAGE-324 (BIIB124) for treating essential tremor (ET). The study failed to demonstrate a statistically significant dose-response relationship or any significant differences between SAGE-324 doses and placebo in reducing tremor severity. Key findings include:
- No statistically significant improvements in the primary endpoint (TETRAS Performance Subscale Item 4 total score) or secondary endpoint (TETRAS Activities of Daily Living Composite Score)
- 147 participants were randomized to placebo, 15 mg, 30 mg, or 60 mg doses
- Common side effects included somnolence, dizziness, and fatigue
- Dose-related increases in CNS depressant side effects were observed
As a result, Sage and Biogen will discontinue further clinical development of SAGE-324 for essential tremor.
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company focused on brain health, has announced it will host a live webcast on Wednesday, July 31, 2024, at 4:30 p.m. ET. The webcast will cover the company's second quarter 2024 financial results and provide updates on recent business activities. Investors and interested parties can access the webcast through the Investor page on Sage's website at investor.sagerx.com. A replay of the webcast will be available after the event and archived for up to 30 days.
Sage Therapeutics announced topline results from its Phase 2 SURVEYOR Study for Huntington's Disease (HD). The study met its primary endpoint, highlighting a significant cognitive difference between healthy participants and those with HD, as measured by the HD-Cognitive Assessment Battery (HD-CAB).
Dalzanemdor (SAGE-718) was generally well-tolerated, with no new safety signals observed. The study involved 40 participants with HD and 29 healthy controls. While the study wasn't designed to show a significant difference between dalzanemdor and placebo, a small numerical improvement was noted in cognition for those on dalzanemdor.
Sage plans to apply these findings to future research and expects to report further data from the dalzanemdor program in late 2024, including studies on Alzheimer's Disease and additional HD cognitive impairment.
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company focused on brain health, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will include a fireside chat scheduled for June 12, 2024, at 2:00 p.m. ET in Miami, FL. Interested parties can view a live webcast of the presentation on Sage's Investor page. A replay will be available for 30 days post-event.
Sage Therapeutics, a biopharmaceutical company, will participate in investor conferences in May, including the 2024 RBCCM Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The Company aims to create a world with better brain health. Live webcasts and replays of the presentations will be available on Sage's Investor page.
FAQ
What is the current stock price of Sage Therapeutics (SAGE)?
What is the market cap of Sage Therapeutics (SAGE)?
What is Sage Therapeutics, Inc. focused on?
What are the key focus areas of Sage Therapeutics?
What are some of the main products of Sage Therapeutics?
What is SAGE-547?
What are the current projects in Sage Therapeutics' pipeline?
What receptor systems does Sage Therapeutics target?
When was Sage Therapeutics founded?
Who makes up the team at Sage Therapeutics?
What is the mission of Sage Therapeutics?
How does Sage Therapeutics enhance its research and development capabilities?
